Back to Results


Title Antihypertensive Treatment of Acute Cerebral Hemorrhage
Therapeutic Area Intracerebral Hemorrhage
Principal Investigator Joshua Kornbluth, MD
Min Age 18 Years
Gender Both
Contact Haley Huggins
More Information


The purpose of this study is to find out if there is a benefit to reducing systolic blood pressure (SBP) in a more intensive way (keeping SBP less than 140 mmHg) compared with the standard way (keeping SBP less than 180 mmHg). This study is using an FDA approved drug called Nicardipine hydrochloride that is routinely used in treatment of patients with intracerebral hemorrhage. IV Nicardipine is a drug that reduces high blood pressure. While reduction of SBP to 140 mmHg may potentially benefit subjects, it is also unknown whether such a reduction is worse for patients. A patient will have an equal chance of being in either group, and the decision will be made randomly through a computer system.

Study Details

Inclusion Criteria

  • Randomized within 4.5 hours of symptom onset
  • Need clinical signs consistent with the diagnosis of stroke
  • INR value < 1.5

Exclusion Criteria

  • ICH is due to previously known neoplasms, AVM, or aneurysms
  • Known sensitivity to Nicardipine
  • Current pregnancy

Study Requirements

Number of research visits: There will be a baseline visit which is considered when a patient arrives at the hospital. While a patient is in the hospital, there will be assessments done at 24 hours, 48 hours, 72 hours, and on Day 7 or discharge (whichever comes first). There will be a telephone follow-up (20-30 minutes) on Day 30 and a follow-up visit (30 minutes) on Day 90 in the outpatient clinic.

Length of participation: 90 days

Number of blood collections: 4

Volume of  blood collected: 1-2 tablespoons per draw

Frequency of blood pressure measurements: every 15-20 minutes while on study drug

Number of CT scans: 2

Number of EKGs: 1